Skip to main content
. 2017 Jan 17;12(1):e0163509. doi: 10.1371/journal.pone.0163509

Fig 2. The cumulative risk of CIN3+ at 24 months* by age and management subgroup.

Fig 2

The 24-month risk of CIN3+ in women with LSIL with a negative test in last 2 years (accepted risk for 12-month repeat recommendation under the pre-renewed NCSP) is shown as the horizontal line in each graph. *The risk was evaluated in unvaccinated cohorts. It was assumed that the risk in cohorts offered vaccination would be equal to or lower than in unvaccinated cohorts (due to potential the impact of vaccine cross-protection against OHR HPV types).